Literature DB >> 6421875

Two distinct forms of Factor VIII coagulant protein in human plasma. Cleavage by thrombin, and differences in coagulant activity and association with von Willebrand factor.

M J Weinstein, L E Chute.   

Abstract

We have characterized Factor VIII coagulant protein, present in normal human plasma, that reacts with a specific human 125I-labeled anti-human VIII:C antigen Fab antibody fragment. Two major Factor VIII coagulant antigen populations were present. The first, approximately 85% of the total antigen, was bound to von Willebrand factor and when tested in a standard one-stage assay had Factor VIII coagulant activity. The second antigenic population, eluting near fibrinogen when plasma was gel filtered, was not bound to von Willebrand protein, did not have Factor VIII coagulant activity unless activated, but did block anti-VIII:C Fab neutralization of clotting activity. The two antigenic populations were separable by cryoprecipitation and agarose gel electrophoresis. Although the two antigenic populations differed in their Factor VIII coagulant activity and in their binding to von Willebrand factor, the principal member of both populations is of mol wt 2.4 X 10(5). Both antigens, when proteolyzed by thrombin, were quickly converted to a 1 X 10(5)-mol wt form in association with the appearance of VIII:C activity. The 1 X 10(5)-mol wt antigen was further slowly degraded to an 8 X 10(4)-mol wt form while Factor VIII coagulant activity declined. These results demonstrate the presence of an inactive Factor VIII coagulant protein in plasma, not associated with von Willebrand factor, that can react with thrombin to yield Factor VIII coagulant activity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6421875      PMCID: PMC425020          DOI: 10.1172/JCI111215

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  Solid-phase immunoradiometric assay of factor-VIII protein.

Authors:  R B Counts
Journal:  Br J Haematol       Date:  1975-12       Impact factor: 6.998

2.  The importance of activation of antihemophilic globulin and proaccelerin by traces of thrombin in the generation of intrinsic prothrombinase activity.

Authors:  S I RAPAPORT; S SCHIFFMAN; M J PATCH; S B AMES
Journal:  Blood       Date:  1963-02       Impact factor: 22.113

3.  The properties of immune complexes formed by human antibodies to factor VIII.

Authors:  J Lazarchick; L W Hoyer
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

4.  Correction by factor VIII of the impaired platelet adhesion to subendothelium in von Willebrand disease.

Authors:  H J Weiss; H R Baumgartner; T B Tschopp; V T Turitto; D Cohen
Journal:  Blood       Date:  1978-02       Impact factor: 22.113

5.  Molecular forms of antihaemophilic globulin in plasma, cryoprecipitate and after thrombin activation.

Authors:  H J Weiss; S Kochwa
Journal:  Br J Haematol       Date:  1970-01       Impact factor: 6.998

6.  Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.

Authors:  H J Weiss; I I Sussman; L W Hoyer
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

7.  Immunologic studies of antihemophilic factor (AHF, factor VIII). V. Immunologic properties of AHF subunits produced by salt dissociation.

Authors:  M E Rick; L W Hoyer
Journal:  Blood       Date:  1973-11       Impact factor: 22.113

8.  Immunoradiometric measurement of the factor VIII procoagulant antigen.

Authors:  J Lazarchick; L W Hoyer
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

9.  The defect in hemophilic and von Willebrand's disease plasmas studied by a recombination technique.

Authors:  H A Cooper; R H Wagner
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

10.  Interaction of factor VIII antigen in hemophilic plasmas with human antibodies to factor VIII.

Authors:  T S Zimmerman; L de la Pointe; T S Edgington
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

View more
  4 in total

1.  Structural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and STEM mass analysis.

Authors:  M W Mosesson; D N Fass; P Lollar; J P DiOrio; C G Parker; G J Knutson; J F Hainfeld; J S Wall
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

2.  Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation.

Authors:  M J Weinstein; L E Chute; G W Schmitt; R H Hamburger; K A Bauer; J H Troll; P Janson; D Deykin
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

3.  Structural basis of von Willebrand factor binding to platelet glycoprotein Ib and collagen. Effects of disulfide reduction and limited proteolysis of polymeric von Willebrand factor.

Authors:  P Bockenstedt; J M Greenberg; R I Handin
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

4.  FVIII half-life extension by coadministration of a D'D3 albumin fusion protein in mice, rabbits, rats, and monkeys.

Authors:  Sabine Pestel; Hans-Wilhelm Beltz; Philipp Claar; Holger Lind; Marcel Mischnik; Elmar Raquet; Arna Andrews; Jason Simmonds; Vesna Tomasetig; Steven K Dower; Anna Tjärnlund-Wolf; Stefan Schulte; Peter M Schmidt; Thomas Weimer
Journal:  Blood Adv       Date:  2020-05-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.